Business Wire

Adversaries Continue Cyberattack Onslaught with Greater Precision and Innovative Attack Methods according to 1H2022 NETSCOUT DDoS Threat Intelligence Report

27.9.2022 13:05:00 EEST | Business Wire | Press release

Share

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today announced findings from its 1H2022 DDoS Threat Intelligence Report. The findings demonstrate how sophisticated cybercriminals have become at bypassing defenses with new DDoS attack vectors and successful methodologies.

"By constantly innovating and adapting, attackers are designing new, more effective DDoS attack vectors or doubling down on existing effective methodologies," said Richard Hummel, threat intelligence lead, NETSCOUT. "In the first half of 2022, attackers conducted more pre-attack reconnaissance, exercised a new attack vector called TP240 PhoneHome, created a tsunami of TCP flooding attacks, and rapidly expanded high-powered botnets to plague network-connected resources. In addition, bad actors have openly embraced online aggression with high-profile DDoS attack campaigns related to geopolitical unrest, which have had global implications."

Deployed in most of the world's ISPs, large data centers, and government and enterprise networks, NETSCOUT Arbor DDoS attack protection solutions send anonymized DDoS attack statistics to NETSCOUT's Active Level Threat Analysis System (ATLAS™). This data, which includes visibility into more than 190 countries, 550 industries, and 50,000 autonomous system numbers (ASNs), is then analyzed and curated by NETSCOUT's ATLAS Security Engineering and Response Team (ASERT) to provide unique insights in the report. No other vendor sees and knows more about DDoS attack activity and best practices in protection than NETSCOUT.

Key findings from the 1H2022 NETSCOUT DDoS Threat Intelligence Report include:

  • There were 6,019,888 global DDoS attacks in 1st half of 2022.
  • TCP-based flood attacks (SYN, ACK, RST) remain the most used attack vector, with approximately 46% of all attacks continuing a trend that started in early 2021.
  • DNS water-torture attacks accelerated into 2022 with a 46% increase primarily using UDP query floods, while carpet-bombing attacks experienced a big comeback toward the end of the second quarter; overall, DNS amplification attacks decreased by 31% from 2H2021 to 1H2022.
  • The new TP240 PhoneHome reflection/amplifications DDoS vector was discovered in early 2022 with a record-breaking amplification ratio of 4,293,967,296:1; swift actions eradicated the abusable nature of this service.
  • Malware botnet proliferation grew at an alarming rate, with 21,226 nodes tracked in the first quarter to 488,381 nodes in the second, resulting in more direct-path, application-layer attacks.

Geopolitical Unrest Spawns Increased DDoS Attacks
As Russian ground troops entered Ukraine in late February, there was a significant uptick in DDoS attacks targeting governmental departments, online media organizations, financial firms, hosting providers, and cryptocurrency-related firms, as previously documented. However, the ripple effect resulting from the war had a dramatic impact on DDoS attacks in other countries too, including:

  • Ireland experienced a surge in attacks after providing service to Ukrainian organizations.
  • India experienced a measurable increase in DDoS attacks following its abstention from the UN Security Council and General Assembly votes condemning Russia's actions in Ukraine.
  • On the same day, Taiwan endured its single-highest number of DDoS attacks after making public statements supporting Ukraine, as with Belize.
  • Finland experienced a 258% increase in DDoS attacks year-over-year, coinciding with its announcement to apply for NATO membership.
  • Poland, Romania, Lithuania, and Norway were targeted by DDoS attacks linked to Killnet; a group of online attackers aligned with Russia.
  • While the frequency and severity of DDoS attacks in North America remained relatively consistent, satellite telecommunications providers experienced an increase in high-impact DDoS attacks, especially after providing support for Ukraine's communications infrastructure.
  • Russia experienced a nearly 3X increase in daily DDoS attacks since the conflict with Ukraine began and continued through the end of the reporting period.

Similarly, as tensions between Taiwan, China, and Hong Kong escalated in 1H2022, DDoS attacks against Taiwan regularly occurred in concert with related public events.

NETSCOUT's DDoS Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's ATLAS and expert insights from ASERT.

The visibility and insights compiled from the global DDOS attack data, represented in the DDoS Threat Intelligence Report, and seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed (AIF). In addition, AIF continuously arms NETSCOUT's Omnis and Arbor security portfolio enabling them to automatically detect and block threat activity for enterprises and service providers worldwide.

Visit our interactive website for more information on NETSCOUT's semi-annual DDoS Threat Intelligence Report. You can also find us on Facebook, LinkedIn , and Twitter for threat updates and the latest trends and insights.

About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance disruptions through advanced network detection and response and pervasive network visibility. Powered by our pioneering deep packet inspection at scale, we serve the world's largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.

©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Editorial Contacts:

Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com

Chris Shattuck
Finn Partners for NETSCOUT
+1 678 504 6785
NETSCOUT-US@FinnPartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye